Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.74 |
| ▸ | NAAA | Q02083 | 1/20 | 0.69 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.66 |
| ▸ | FAAH | O00519 | 4/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RRM1 | P23921 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24412649 | 1.00 | CASP2 (0.74) | CASP2NAAASLC6A5FAAHEPHX1 | |
| SCHEMBL27836368 | 1.00 | CASP2 (0.74) | CASP2NAAASLC6A5FAAHEPHX1 | |
| SCHEMBL28688783 | 1.00 | CASP2 (0.74) | CASP2NAAASLC6A5FAAHEPHX1 | |
| SCHEMBL13019125 | 1.00 | CASP2 (0.74) | CASP2NAAASLC6A5FAAHEPHX1 | |
| SCHEMBL11739321 | 1.00 | CASP2 (0.74) | CASP2NAAASLC6A5FAAHEPHX1 | |
| Hydrochloric Acid SCHEMBL20542987 | 0.98 | CASP2 (0.71) | CASP2NAAASLC6A5FAAHEPHX1 | |
| Hydrochloric Acid SCHEMBL23000981 | 0.98 | CASP2 (0.71) | CASP2NAAASLC6A5FAAHEPHX1 | |
| SCHEMBL7700850 | 0.98 | CASP2 (0.70) | CASP2NAAASLC6A5FAAHEPHX1 | |
| SCHEMBL3550215 | 0.92 | CASP2 (0.61) | CASP2NAAASLC6A5FAAHEPHX1 | |
| SCHEMBL22522082 | 0.90 | SLC6A5 (0.64) | CASP2NAAASLC6A5FAAHDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021252290-A2 | COMPOSITIONS AND METHODS FOR TREATING NOVEL CORONAVIRUS SARS-COV-2-MEDIATED INFLAMMATORY CONDITIONS | GRI BIO, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| CN-1059658-A | The method of stabilized liposome and the compositions that contains them | JOHNSON & SON INC S C (US) | 1992-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | CASP2 248/4885NAAA 2859/4885SLC6A5 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.